Soligenix Inc. (SNGX) is a development stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestional diseases, and vaccines for certain bioterrorism agents. Soligenix has two areas of focus:
- Therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as pediatric Crohn’s disease, acute radiation enteritis, and Graft-versus-Host disease (GVHD), and
- A vaccine/biodefense segment to develop vaccines and therapeutics for military and civilian applications.
The Company has released an updated corporate presentation, current as of April 2012. The presentation includes information about the company’s value proposition, senior management team, indepedent board directors, pipeline, market potential, past and future milestones, and more.
Below is the value proposition:
Corporate
- Diversified portfolio: BioTherapeutics and Vaccines/BioDefense
- Multiple programs in rare disease and areas of unmet medical need
- Significant NIH/FDA grant support for most programs
- Experienced management and board of directors
- End of first quarter 2012 cash approximately $6 million
- Clean capital structure with no debt or preferred stock outstanding
- Largest shareholder Sigma-Tau; approximately 26% ownership
BioTherapeutics
- Oral BDP application for inflammatory gastrointestinal (GI) indications – acute radiation enteritis and pediatric Crohn’s Disease; markets in excess of $500 million worldwide
- 35% royalty generating partnership with Sigma-Tau on orBec®/oral BDP for North America and Europe
Vaccines/BioDefense
- ThermoVaxTM heat stabilization technology capable of eliminating cold chain distribution and storage concerns
- Grant funded and revenue generating – $9.4 million NIH grant award
- 3 novel BioDefense development candidates
-
RiVaxTM – a world leader in ricin toxin vaccine research
-
SGX202 (oral BDP) – compelling pre-clinical results in GI acute radiation syndrome (ARS)
-
SGX204 – novel hyperimmunogenic anthrax vaccine from Harvard
View the full presentation below.